Morgan Stanley’s BiomX PHGE Stock Holding History

Morgan Stanley’s Portfolio PHGE Stock Details PHGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,100	Closed	-$71.7K	–	8543
2026 Q1	$71.7K	Buy	+19,100	New	+$90.1K	﹤0.01%	6286
2025 Q3	–	Sell	-97,581	Closed	-$834K	–	8312
2025 Q2	$834K	Buy	+97,581	New	+$974K	﹤0.01%	5201
2022 Q1	–	Sell	-21	Closed	-$6K	–	8078
2021 Q4	$6K	Buy	21 +10	+91%	+$4K	﹤0.01%	7606
2021 Q3	$6K	Hold	11	–	–	﹤0.01%	7454
2021 Q2	$11K	Hold	11	–	–	﹤0.01%	7208
2021 Q1	$14K	Buy	+11	New	+$14.9K	﹤0.01%	6845

Other funds holding PHGE

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley's PHGE Position: Q2 2026 in Review

Morgan Stanley sold out of BiomX (PHGE) in Q2 2026, closing a stake of 19,100 shares — an estimated $71.7K sold.

Morgan Stanley first reported a position in PHGE in Q1 2021 and held it in 6 quarters. The position peaked at $834K in Q2 2025. 9 funds tracked by Wall St. Rank hold PHGE as of Q2 2026.

Morgan Stanley reported no remaining BiomX position as of Q2 2026 after selling out during the quarter.
Morgan Stanley sold 19,100 BiomX shares in Q2 2026, an estimated $71.7K.
Morgan Stanley first reported a position in BiomX in Q1 2021 and held it in 6 quarters.
Morgan Stanley's BiomX position peaked at $834K in Q2 2025.
9 funds tracked by Wall St. Rank held BiomX as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.